Aucta FDA Thursday, April 9, 2026 0.00 Neutral

FDA Approves FOSFOMYCIN TROMETHAMINE — Aucta Pharmaceuticals, Inc.

# FDA Approves Generic Fosfomycin Tromethamine, Expanding Treatment Options for Urinary Tract Infections Aucta Pharmaceuticals, Inc. received FDA approval for its generic formulation of fosfomycin tromethamine, an oral antibiotic used to treat uncomplicated urinary tract infections, potentially increasing competition in the market and improving patient access to this therapeutic option. The approval is expected to drive price competition and expand treatment availability as healthcare providers gain an additional supplier for this commonly prescribed infection treatment.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day